Investment, Q and epidemic diseases

We study the effects of epidemic diseases on corporate investment. Epidemic diseases tend to be unanticipated and exogenous to firms’ decisions. Using difference-in-difference estimation strategy and a firm-level exposure to an epidemic disease measure, we find that corporate investment declines sig...

Descripción completa

Detalles Bibliográficos
Autor principal: Tut, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090821/
https://www.ncbi.nlm.nih.gov/pubmed/35571984
http://dx.doi.org/10.1016/j.frl.2022.102943
_version_ 1784704806771752960
author Tut, Daniel
author_facet Tut, Daniel
author_sort Tut, Daniel
collection PubMed
description We study the effects of epidemic diseases on corporate investment. Epidemic diseases tend to be unanticipated and exogenous to firms’ decisions. Using difference-in-difference estimation strategy and a firm-level exposure to an epidemic disease measure, we find that corporate investment declines significantly following the onset of an epidemic disease. We also show that the COVID-19 pandemic has the strongest negative impact on investment when compared to the other most recent epidemic diseases.
format Online
Article
Text
id pubmed-9090821
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-90908212022-05-11 Investment, Q and epidemic diseases Tut, Daniel Financ Res Lett Article We study the effects of epidemic diseases on corporate investment. Epidemic diseases tend to be unanticipated and exogenous to firms’ decisions. Using difference-in-difference estimation strategy and a firm-level exposure to an epidemic disease measure, we find that corporate investment declines significantly following the onset of an epidemic disease. We also show that the COVID-19 pandemic has the strongest negative impact on investment when compared to the other most recent epidemic diseases. Elsevier Inc. 2022-06 2022-05-11 /pmc/articles/PMC9090821/ /pubmed/35571984 http://dx.doi.org/10.1016/j.frl.2022.102943 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Tut, Daniel
Investment, Q and epidemic diseases
title Investment, Q and epidemic diseases
title_full Investment, Q and epidemic diseases
title_fullStr Investment, Q and epidemic diseases
title_full_unstemmed Investment, Q and epidemic diseases
title_short Investment, Q and epidemic diseases
title_sort investment, q and epidemic diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090821/
https://www.ncbi.nlm.nih.gov/pubmed/35571984
http://dx.doi.org/10.1016/j.frl.2022.102943
work_keys_str_mv AT tutdaniel investmentqandepidemicdiseases

Ejemplares similares